2Seventy Bio Ownership
| TSVT Stock | USD 3.99 0.03 0.76% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
2Seventy |
2Seventy Stock Ownership Analysis
About 91.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. 2Seventy Bio recorded a loss per share of 1.83. The entity had not issued any dividends in recent years. 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people. To find out more about 2Seventy Bio contact the company at 617 675 7270 or learn more at https://www.2seventybio.com.Besides selling stocks to institutional investors, 2Seventy Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different 2Seventy Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align 2Seventy Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
2Seventy Bio Quarterly Liabilities And Stockholders Equity |
|
2Seventy Bio Insider Trades History
About 4.0% of 2Seventy Bio are currently held by insiders. Unlike 2Seventy Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against 2Seventy Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of 2Seventy Bio's insider trades
2Seventy Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 2Seventy Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 2Seventy Bio backward and forwards among themselves. 2Seventy Bio's institutional investor refers to the entity that pools money to purchase 2Seventy Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | State Street Corp | 2024-06-30 | 1 M | Eversept Partners, Llc | 2024-09-30 | 998.1 K | Cowen And Company, Llc | 2024-06-30 | 800 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 667 K | Dafna Capital Management Llc | 2024-09-30 | 630 K | Bank Of America Corp | 2024-06-30 | 606.8 K | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 590 K | Jpmorgan Chase & Co | 2024-06-30 | 532.4 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.5 M | Kynam Capital Management, Lp | 2024-09-30 | 6 M |
2Seventy Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 2Seventy Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on 2Seventy Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 2Seventy Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
2Seventy Bio Outstanding Bonds
2Seventy Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 2Seventy Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 2Seventy bonds can be classified according to their maturity, which is the date when 2Seventy Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| US90138FAC68 Corp BondUS90138FAC68 | View | |
| US90138FAD42 Corp BondUS90138FAD42 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
2Seventy Bio Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 6th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.